GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.